Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT02362646
Previous Study | Return to List | Next Study

Safety & Efficacy of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function in LVAD Recipients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02362646
Recruitment Status : Active, not recruiting
First Posted : February 13, 2015
Last Update Posted : December 4, 2018
Sponsor:
Collaborator:
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by (Responsible Party):
Annetine Gelijns, Icahn School of Medicine at Mount Sinai

Tracking Information
First Submitted Date  ICMJE February 9, 2015
First Posted Date  ICMJE February 13, 2015
Last Update Posted Date December 4, 2018
Study Start Date  ICMJE July 2015
Actual Primary Completion Date August 10, 2018   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: April 29, 2015)
  • Functional Status [ Time Frame: up to 6 months ]
    functional status, defined by the number of temporary weans from LVAD support tolerated over the 6 months post-randomization. A successful wean is the ability to tolerate temporary weaning from LVAD support for 30 minutes without sustained symptoms of worsening heart failure. Wean failures are defined as inability to tolerate the temporary wean for 30 minutes; death; or patient too unstable, in the judgment of the primary heart failure cardiologist, to tolerate the wean attempt.
  • Number of participants with adverse events [ Time Frame: up to 12 months ]
    Safety: Incidence of the study intervention-related adverse events
Original Primary Outcome Measures  ICMJE
 (submitted: February 12, 2015)
  • Functional Status [ Time Frame: up to 12 months ]
    functional status, defined by the number of temporary weans from LVAD support tolerated over the 12 months post-randomization. A successful wean is the ability to tolerate temporary weaning from LVAD support for 30 minutes without sustained symptoms of worsening heart failure. Wean failures are defined as inability to tolerate the temporary wean for 30 minutes; death; or patient too unstable, in the judgment of the primary heart failure cardiologist, to tolerate the wean attempt.
  • Number of participants with adverse events [ Time Frame: up to 12 months ]
    Safety: Incidence of the study intervention-related adverse events
Change History Complete list of historical versions of study NCT02362646 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: April 29, 2015)
  • Physiologic Assessments [ Time Frame: up to 12 months ]
    Echocardiographic assessments of the myocardial size and function by transthoracic echocardiography with LVAD at full support, and as tolerated following 6-Minute Walk Test (MWT) while weaned from LVAD support (for patients who tolerate wean from LVAD support for 30 minutes)
  • Histopathological assessments of myocardial tissue [ Time Frame: up to 12 months ]
  • Overall Survival [ Time Frame: up to 12 months ]
  • Change in Quality of Life (QoL) [ Time Frame: 6 months and 12 months ]
    Quality of life will be assessed with the Kansas City Cardiomyopathy Questionnaire (KCCQ), a widely used tool in heart failure populations, and the Short Form 12 (SF12), a widely used overall health status measure.
  • Hopkins Verbal Learning Test [ Time Frame: 3 months and 12 months ]
    Cognitive performance will be assessed Hopkins Verbal Learning Test. Neurocognitive testing will be administered by clinical site personnel who have been trained and certified for test administration by the Neurocognitive Core lab personnel.
  • Trailmaking Tests A and B [ Time Frame: 3 months and 12 months ]
    Cognitive performance will be assessed using Trailmaking Tests A and B. Neurocognitive testing will be administered by clinical site personnel who have been trained and certified for test administration by the Neurocognitive Core lab personnel.
  • MCG Complex Figures [ Time Frame: 3 months and 12 months ]
    Cognitive performance will be assessed using the MCG Complex Figures. Neurocognitive testing will be administered by clinical site personnel who have been trained and certified for test administration by the Neurocognitive Core lab personnel.
  • Digit Span [ Time Frame: 3 months and 12 months ]
    Cognitive performance will be assessed using the MCG Complex Figures. Neurocognitive testing will be administered by clinical site personnel who have been trained and certified for test administration by the Neurocognitive Core lab personnel.
  • Digit Symbol Substitution Test [ Time Frame: 3 months and 12 months ]
    Cognitive performance will be assessed using the Digit Symbol Substitution Test. Neurocognitive testing will be administered by clinical site personnel who have been trained and certified for test administration by the Neurocognitive Core lab personnel.
  • Controlled Oral Word Association [ Time Frame: 3 months and 12 months ]
    Cognitive performance will be assessed using the Controlled Oral Word Association. Neurocognitive testing will be administered by clinical site personnel who have been trained and certified for test administration by the Neurocognitive Core lab personnel.
  • Length of Stay [ Time Frame: up to 12 months ]
    Length of stay of index hospitalization
  • Hospitalizations [ Time Frame: up to 12 months ]
    Frequency and cause of readmissions
  • Hospital Costs [ Time Frame: up to 12 months ]
    Hospital resource use
  • Functional Status [ Time Frame: up to 12 months ]
    functional status, defined by the number of temporary weans from LVAD support tolerated
Original Secondary Outcome Measures  ICMJE
 (submitted: February 12, 2015)
  • Physiologic Assessments [ Time Frame: up to 12 months ]
    Echocardiographic assessments of the myocardial size and function by transthoracic echocardiography with LVAD at full support, and as tolerated following 6-Minute Walk Test (MWT) while weaned from LVAD support (for patients who tolerate wean from LVAD support for 30 minutes)
  • Histopathological assessments of myocardial tissue [ Time Frame: up to 12 months ]
  • Overall Survival [ Time Frame: up to 12 months ]
  • Change in Quality of Life (QoL) [ Time Frame: 6 months and 12 months ]
    Quality of life will be assessed with the Kansas City Cardiomyopathy Questionnaire (KCCQ), a widely used tool in heart failure populations, and the Short Form 12 (SF12), a widely used overall health status measure.
  • Hopkins Verbal Learning Test [ Time Frame: 3 months and 12 months ]
    Cognitive performance will be assessed Hopkins Verbal Learning Test. Neurocognitive testing will be administered by clinical site personnel who have been trained and certified for test administration by the Neurocognitive Core lab personnel.
  • Trailmaking Tests A and B [ Time Frame: 3 months and 12 months ]
    Cognitive performance will be assessed using Trailmaking Tests A and B. Neurocognitive testing will be administered by clinical site personnel who have been trained and certified for test administration by the Neurocognitive Core lab personnel.
  • MCG Complex Figures [ Time Frame: 3 months and 12 months ]
    Cognitive performance will be assessed using the MCG Complex Figures. Neurocognitive testing will be administered by clinical site personnel who have been trained and certified for test administration by the Neurocognitive Core lab personnel.
  • Digit Span [ Time Frame: 3 months and 12 months ]
    Cognitive performance will be assessed using the MCG Complex Figures. Neurocognitive testing will be administered by clinical site personnel who have been trained and certified for test administration by the Neurocognitive Core lab personnel.
  • Digit Symbol Substitution Test [ Time Frame: 3 months and 12 months ]
    Cognitive performance will be assessed using the Digit Symbol Substitution Test. Neurocognitive testing will be administered by clinical site personnel who have been trained and certified for test administration by the Neurocognitive Core lab personnel.
  • Controlled Oral Word Association [ Time Frame: 3 months and 12 months ]
    Cognitive performance will be assessed using the Controlled Oral Word Association. Neurocognitive testing will be administered by clinical site personnel who have been trained and certified for test administration by the Neurocognitive Core lab personnel.
  • Length of Stay [ Time Frame: up to 12 months ]
    Length of stay of index hospitalization
  • Hospitalizations [ Time Frame: up to 12 months ]
    Frequency and cause of readmissions
  • Hospital Costs [ Time Frame: up to 12 months ]
    Hospital resource use
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Safety & Efficacy of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function in LVAD Recipients
Official Title  ICMJE Safety & Efficacy of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function in LVAD Recipients
Brief Summary The main purpose of this research is to determine whether injecting mesenchymal precursor cells (MPC) into the heart during surgery to implant a left ventricular assist device (LVAD) is safe. MPCs are normally present in human bone marrow and have been shown to increase the development of blood vessels and new heart muscle cells in the heart. In addition, this research is being done to test whether injecting the MPCs into the heart is effective in improving heart function.
Detailed Description Intramyocardial injection of mesenchymal precursor cells (MPC) in patients with advanced heart failure who are treated with left ventricular assist device (LVAD) implantation may result in a renewable source of proliferating functional cardiomyocytes; induce development of capillaries and larger-size blood vessels to supply oxygen and nutrients to endogenous myocardium and newly-implanted cardiomyocytes; and release factors capable of paracrine signaling.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE
  • Heart Failure
  • Cardiomyopathy
  • Ventricular Dysfunction
Intervention  ICMJE
  • Biological: MPC Intramyocardial Injection
    Intramyocardial injection of 150 million mesenchymal precursor cells at the time of LVAD implantation
    Other Names:
    • Mesenchymal Precursor Cell Injection
    • RevascorTM
  • Drug: Control Solution
    Other Names:
    • 50% Alpha-MEM/42.5% ProFreeze NAO Freezing Medium/7.5% DMSO
    • Cryoprotective media
Study Arms  ICMJE
  • Experimental: MPC Intramyocardial Injection
    Intramyocardial injections of 150 million MPCs
    Intervention: Biological: MPC Intramyocardial Injection
  • Sham Comparator: Control Solution
    Intramyocardial injections of 50% Alpha-MEM/42.5% ProFreeze NAO Freezing Medium/7.5% DMSO
    Intervention: Drug: Control Solution
Publications * Yau TM, Pagani FD, Mancini DM, Chang HL, Lala A, Woo YJ, Acker MA, Selzman CH, Soltesz EG, Kern JA, Maltais S, Charbonneau E, Pan S, Marks ME, Moquete EG, O'Sullivan KL, Taddei-Peters WC, McGowan LK, Green C, Rose EA, Jeffries N, Parides MK, Weisel RD, Miller MA, Hung J, O'Gara PT, Moskowitz AJ, Gelijns AC, Bagiella E, Milano CA; Cardiothoracic Surgical Trials Network. Intramyocardial Injection of Mesenchymal Precursor Cells and Successful Temporary Weaning From Left Ventricular Assist Device Support in Patients With Advanced Heart Failure: A Randomized Clinical Trial. JAMA. 2019 Mar 26;321(12):1176-1186. doi: 10.1001/jama.2019.2341.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Actual Enrollment  ICMJE
 (submitted: December 9, 2016)
159
Original Estimated Enrollment  ICMJE
 (submitted: February 12, 2015)
120
Estimated Study Completion Date  ICMJE August 2019
Actual Primary Completion Date August 10, 2018   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Signed informed consent, inclusive of release of medical information, and Health Insurance Portability and Accountability Act (HIPAA) documentation

    • Age 18 years or older
    • If the subject or partner is of childbearing potential, he or she must be willing to use adequate contraception (hormonal or barrier method or abstinence) from the time of screening and for a period of at least 16 weeks after procedure
    • Female subjects of childbearing potential must have a negative serum pregnancy test at screening
    • Admitted to the clinical center at the time of randomization
    • Clinical indication and accepted candidate for implantation of an FDA-approved (US sites only) or Health Canada-approved (Canadian sites only) implantable, non-pulsatile LVAD as a bridge to transplantation or for destination therapy.

Exclusion Criteria:

  • Planned percutaneous LVAD implantation

    • Anticipated requirement for biventricular mechanical support
    • Concomitant arrhythmia ablation at time of LVAD implantation

      -- Planned aortic valve intervention for aortic insufficiency at the time of LVAD implantation

    • Cardiothoracic surgery within 30 days prior to randomization
    • Spontaneous myocardial infarction related to ischemia due to a primary coronary event such as unstable plaque rupture, erosion or dissection within 30 days prior to randomization
    • Prior cardiac transplantation, LV reduction surgery, or cardiomyoplasty
    • Acute reversible cause of heart failure (e.g. myocarditis, profound hypothyroidism)
    • Stroke within 30 days prior to randomization
    • Platelet count < 100,000/ul within 24 hours prior to randomization
    • Acute infectious process: acute bacterial, fungal, or viral disease OR acute exacerbation of chronic infectious disease such as hepatitis
    • Presence of >10% anti-HLA antibody titers with known specificity to MPC donor HLA antigens
    • A known hypersensitivity to dimethyl sulfoxide (DMSO), murine, and/or bovine products
    • History of a known active malignancy within the past 3 years except for localized prostate cancer, cervical carcinoma in situ, breast cancer in situ, or nonmelanoma skin cancer that has been definitively treated
    • Presence of human immunodeficiency virus (HIV)
    • Received investigational intervention within 30 days prior to randomization
    • Treatment and/or an incomplete follow-up treatment of any investigational cell based therapy within 6 months prior to randomization
    • Active participation in other research therapy for cardiovascular repair/regeneration
    • Prior recipient of stem precursor cell therapy for cardiac repair
    • Pregnant or breastfeeding at time of randomization.
    • History of known or suspected hypercoagulable state in the opinion of the investigator
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Canada,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02362646
Other Study ID Numbers  ICMJE GCO 08-1078-0008
2U01HL088942-07 ( U.S. NIH Grant/Contract )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Annetine Gelijns, Icahn School of Medicine at Mount Sinai
Study Sponsor  ICMJE Annetine Gelijns
Collaborators  ICMJE National Heart, Lung, and Blood Institute (NHLBI)
Investigators  ICMJE
Study Chair: Patrick O'Gara, MD Brigham and Women's Hospital
Study Chair: Richard Weisel, MD Toronto General Hospital
PRS Account Icahn School of Medicine at Mount Sinai
Verification Date December 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP